ACLS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tang, P.
Right arrow Articles by Hajdu, S. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tang, P.
Right arrow Articles by Hajdu, S. I.
Annals of Clinical & Laboratory Science 36:16-22 (2006)
© 2006 Association of Clinical Scientists

Relationship between Nuclear Grade of Ductal Carcinoma in situ and Cell Origin Markers

Ping Tang1, Xi Wang1, Linda Schiffhauer1, Jianmin Wang2, Patricia Bourne1, Qi Yang1, Andrew Quinn1 and Steven I. Hajdu3
1 Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York; 2 RTI Health Solution, Research Triangle Park, North Carolina; 3 New York University School of Medicine, New York, New York

Address correspondence to Ping Tang, MD, PhD, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center Box 626, 601 Elmwood Ave, Rochester, NY 14642, USA; tel 585 275 6640; fax 585 273 3637; e-mail: ping_tang{at}urmc.rochester.edu.

Ductal carcinoma in situ (DCIS) is a group of heterogeneous lesions genetically, morphologically, and biologically. Recently, breast epithelium in the terminal ductal lobular unit has been sub-classified based on the expression of several cytokeratin markers as stem cells (CK5/6 +), luminal cells (CK8, CK18 +), and basal cells (CK14, CK17 +). In this study we describe the relationship between DCIS of different nuclear grades (non-high grade and high grade) and these cell origin markers. Fifty-three cases of non-high grade and 46 cases of high grade DCIS were selected, and representative sections from each case were stained with antibodies to these cytokeratin markers. High grade DCIS showed significantly higher rates of expression with stem and basal cell markers compared with non-high grade DCIS (p <0.05). The majority of DCIS, both high grade and non-high grade, expressed luminal cell markers (67% to 91%) and single type of cell origin marker (72% to 87%). High-grade DCIS more frequently co-expressed all three types of cell origin markers compared with non-high grade DCIS (p <0.05). In summary, a subset of high grade DCIS frequently rises from stem or/and basal cell populations; the subset is associated with poor prognosis in invasive breast carcinoma. Thus, these markers may be used to identify a potentially more aggressive subgroup of breast carcinoma at its pre-invasive stage (DCIS), and to manage it accordingly. Second, most DCIS express luminal cell markers, suggesting that malignant transformation occurs relatively late along the cell differentiation pathway, contrary to the traditional belief that most neoplasms arise from a more primitive stem cell population. Third, the majority of DCIS exclusively express one type of progenitor marker, indicating that in most incidences they may arise from a single progenitor population. Last, triple expression of all types of cell origin marker is frequently associated with high grade DCIS, suggesting that more complicated pathways are involved in these more aggressive lesions. Further studies are needed to delineate the relationships of cell origin markers in DCIS and invasive carcinoma to the clinical outcome.

Keywords: breast carcinoma, ductal carcinoma in situ, nuclear grade, intraductal carcinoma




This article has been cited by other articles:


Home page
JCOHome page
E. A. Rakha, J. S. Reis-Filho, and I. O. Ellis
Basal-Like Breast Cancer: A Critical Review
J. Clin. Oncol., May 20, 2008; 26(15): 2568 - 2581.
[Abstract] [Full Text] [PDF]


Home page
Annals of Clinical & Laboratory ScienceHome page
P. Tang, X. Wang, L. Schiffhauer, J. Wang, P. Bourne, Q. Yang, A. Quinn, and S. Hajdu
Expression Patterns of ER-{alpha}, PR, HER-2/neu, and EGFR in Different Cell Origin Subtypes of High Grade and Non-High Grade Ductal Carcinoma In Situ.
Ann. Clin. Lab. Sci., March 1, 2006; 36(2): 137 - 143.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Association of Clinical Scientists.